Evaluation of bleeding in patients receiving direct oral anticoagulants
Authors:
Open Access
- 1 August 2017
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 13, 325-342
Abstract
Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.Keywords
This publication has 57 references indexed in Scilit:
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropean Heart Journal, 2016
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009